Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial

Lung Cancer

Volumn 80, Issue 2, 2013, Pages 185-190

  Gervais, Radj ^a   Robinet, Gilles ^b   Clément Duchêne, Christelle ^c   Denis, Fabrice ^d   Kouri, Claude El ^e   Martin, Philippe ^f   Chouaki, Nadia ^g   Bourayou, Nawel ^g   Morère, Jean François ^h  

^a CENTRE FRANÇOIS BACLESSE   (France)

^b CHU MORVAN   (France)

^c CHU NANCY BRABOIS   (France)

^d Clinique Victor Hugo   (France)

^e Centre Catherine de Sienne   (France)

^f Centre Bourgogne   (France)

^g Produits Roche   (France)

^h AVICENNE HOSPITAL   (France)

Author keywords

Carboplatin; Elderly; First line; Non small cell lung cancer; Pemetrexed; Stage IIIB IV

Indexed keywords

CARBOPLATIN; PEMETREXED;

ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW DEPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER STAGING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FEBRILE BONE MARROW APLASIA; FEBRILE NEUTROPENIA; FEMALE; HISTOLOGY; HUMAN; KIDNEY FAILURE; LARGE CELL CARCINOMA; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG TOXICITY; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 84875889240     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.01.008     Document Type: Article

References (24)

1. GLOBOCAN 2008. Cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2008. Available at: [accessed 15.09.11]. http://globocan.iarc.fr/age-specific_table_n_PDF.asp.
2. Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010. , based on November 2009 SEER data submission, posted to the SEER web site. http://seer.cancer.gov/csr/1975_2007/.
3. Talarico L., Chen G., Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004, 22:4626-4631. 12.
4. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
5. Trigo Pérez J.M., Garrido López P., Felip Font E., Isla Casado D. SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. Clin Transl Oncol 2010, 12:735-741. SEOM (Spanish Society for Medical Oncology).
6. D'Addario G., Fruh M., Reck M., Baumann P., Klepetko W., Felip E. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. (5)):v116-v119.
7. Pallis A.G., Gridelli C., van Meerbeeck J.P., Greillier L., Wedding U., Lacombe D., et al. EORTC elderly task force and lung cancer group and international society for geriatric oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol 2010, 21:692-706.
8. Ganti A., DeShazo M., Weir A., Hurria A. Treatment of non-small cell lung cancer in the older patient. JNCCN 2012, 10:230-239.
9. Zinner R.G., Fossella F.V., Gladish G.W., Glisson B.S., Blumenschein G.R., Papadimitrakopoulou V.A., et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer. Cancer 2005, 104:2449-2456.
10. Scagliotti G.V., Kortsik C., Dark G.G., Price A., Manegold C., Rosell R., et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005, 11:690-696.
11. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99:847-857.
12. SPC: . http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000703/WC500021142.pdf.
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
14. Ozer H., Armitage J.O., Bennett C.L., Crawford J., Demetri G.D., Pizzo P.A., et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines, American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000 Oct 15, 18(20):3558-3585.
15. Davidoff A.J., Tang M., Seal B., Edelman M.J. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2191-2197.
16. Lilenbaum R.C., Herndon J.E., List M.A., Desch C., Watson D.M., Miller A.A., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005, 23:190-196.
17. Kim H.J., Kim T.G., Lee H.J., Kim J.H., Lim B.H., Seo J.W., et al. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer 2010, 68:248-252.
18. Quoix E., Zalcman G., Oster J.P., Westeel V., Pichon E., Lavolé A., et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011, 378:1079-1088.
19. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
20. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
21. Gridelli C., Brodowicz T., Langer C.J., Peterson P., Islam M., Guba S.C., et al. Pemetrexed Therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2012, 13(September (5)):340-346.
22. Grønberg B.H., Bremnes R.M., Fløtten O., Amundsen T., Brunsvig P.F., Hjelde H.H., et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27(July (19)):3217-3224.
23. Des Guetz G., Uzzan B., Nicolas P., Chouahnia K., Sebbane G., Morere J.F. Meta-analysis of efficacy and safety of single-agent and doublet chemotherapy with or without platinum in advanced non-small cell lung cancer in the elderly, 2011 ASCO Annual Meeting. J Clin Oncol 2011, 29(Suppl.). [abstr 7547].
24. ESOGIA-GFPC 08-02: Essai de phase 3 randomisé comparant l'intérêt de deux stratégies d'attributions du traitement, classique ou optimisée à l'aide d'une échelle gériatrique simplifiée, chez des patients âgés ayant un cancer bronchique non à petites cellules. http://www.e-cancer.fr/les-essais-cliniques/registre-des-essais-cliniques.